Sarepta Therapeutics (SRPT) jumped on Tuesday's session after the FDA lifted a voluntary pause on the company's gene therapy treatment for patients with Duchenne muscular dystrophy. The drug was pulled earlier this year to determine if it was tied to a patient's death. George Tsilis talks about the possibility of this being an "inflection bottom" for the stock, though analysts remain divided on whether that's actually the case.